However, in a small-scale HNSCC clinical study, an EGFR mutation involving a deletion in exon 19 was associated with a poor response to cetuximab treatment and worse prognosis [78], as shown in Table 3. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.